Akari Therapeutics, Plc Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Akari Therapeutics, Plc (AKTX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $9.99 million for the 6-month period ending 2017-06-30, per its 6-K filed 2017-08-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-10
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|
| 2017-06-30 | $9.99M 6-K · filed 2017-08-10 | |
| 2016-12-31 | -$10.07M 20-F · filed 2017-03-31 | |
| 2016-06-30 | -$46.17M 6-K · filed 2017-08-10 | |
| 2015-12-31 | $1.39M 20-F · filed 2017-03-31 | |
| 2015-06-30 | $0.00 6-K · filed 2017-04-14 | |
| 2014-12-31 | $0.00 20-F · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |